Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study

WOLFGANG SCHULTZE-SEEMANN; HOLGER SCHULZ; BARBARA TSCHECHNE; MANUEL HÄCKL

doi:10.21873/anticanres.13188

Research ArticleClinical Studies

Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study

WOLFGANG SCHULTZE-SEEMANN, HOLGER SCHULZ, BARBARA TSCHECHNE and MANUEL HÄCKL

Anticancer Research February 2019, 39 (2) 875-882; DOI: https://doi.org/10.21873/anticanres.13188

WOLFGANG SCHULTZE-SEEMANN

1University Hospital Freiburg (Albert-Ludwigs-University) Urology, Freiburg, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: wolfgang.schultze-seemann{at}uniklinik-freiburg.de sekretariat.schultze-seemann{at}uniklinik-freiburg.de

HOLGER SCHULZ

2PIOH Study and Management GbR, Frechen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

BARBARA TSCHECHNE

3Specialist for Internal Medicine Hematology and Oncology, Neustadt, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

MANUEL HÄCKL

4Roche Pharma AG Germany, Grenzach-Wyhlen, Germany

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Figures & Data

Figures

Tables

Download figure
Open in new tab
Download powerpoint
Figure 1.
Consort diagram. BEV, Bevacizumab.

Tables

Figures

PreviousNext

In this issue

Anticancer Research

Vol. 39, Issue 2

February 2019

Table of Contents
Table of Contents (PDF)
Index by author
Back Matter (PDF)
Ed Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study

Message Subject (Your Name) has sent you a message from Anticancer Research

Message Body (Your Name) thought you would like to see the Anticancer Research web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Math question * 10 + 8 =

Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Citation Tools

Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study

WOLFGANG SCHULTZE-SEEMANN, HOLGER SCHULZ, BARBARA TSCHECHNE, MANUEL HÄCKL

Anticancer Research Feb 2019, 39 (2) 875-882; DOI: 10.21873/anticanres.13188

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Reprints and Permissions

Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study

WOLFGANG SCHULTZE-SEEMANN, HOLGER SCHULZ, BARBARA TSCHECHNE, MANUEL HÄCKL

Anticancer Research Feb 2019, 39 (2) 875-882; DOI: 10.21873/anticanres.13188

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
PDF

Cited By...

Management of Patients With Metastatic Renal Cell Cancer and Bone Metastases

Google Scholar

Keywords

Renal cell carcinoma
advanced disease
metastatic disease
bevacizumab (Avastin®)
non-interventional study

Main menu

User menu

Search

Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study

Article Figures & Data

Figures

Tables

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Keywords